Frankfurt
07.01.26 | 15:29
8,750 Euro
-1,69 % -0,150
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12.25 | FDA sets new PDUFA date for Fortress Biotech's Menkes disease therapy | 26 | Investing.com | ||
| 15.12.25 | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.25 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 573 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| 14.11.25 | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.11.25 | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 11.11.25 | Fortress Biotech Q3 Earnings Preview | 5 | Seeking Alpha | ||
| 21.10.25 | Fortress Biotech: Aktie legt zu - Gichtmittel der Tochtergesellschaft erreicht Phase-3-Studie | 15 | Investing.com Deutsch | ||
| 21.10.25 | Fortress Biotech stock rises after subsidiary's gout treatment enters Phase 3 trials | 2 | Investing.com | ||
| 21.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 226 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 02.10.25 | FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln | 20 | Investing.com Deutsch | ||
| 02.10.25 | Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101 | 3 | Investing.com | ||
| 01.10.25 | Fortress Biotech stock plummets after FDA rejects Menkes disease drug | 13 | Investing.com | ||
| 01.10.25 | Fortress Biotech plunges as FDA rejects rare disease drug | 20 | Seeking Alpha | ||
| 01.10.25 | Fortress Biotech, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 126 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 174 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen | |
| 21.08.25 | Fortress Biotech stock price target lowered to $17 at H.C. Wainwright | 29 | Investing.com | ||
| 14.08.25 | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08.25 | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 489 | GlobeNewswire (Europe) | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| 16.07.25 | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 314,30 | +0,26 % | Dividendenbekanntmachungen (31.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1702 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1802 EUR AGNC INVESTMENT CORP US00123Q1040 0... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 695,80 | +4,73 % | 21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know | ||
| VIKING THERAPEUTICS | 27,655 | +0,11 % | Viking Therapeutics-Aktie: Hopp oder top? | Die Aktie von Viking Therapeutics steht exemplarisch für die enorme Dynamik im Markt für Abnehmmedikamente und spiegelt zugleich die noch ungelösten Bewertungsfragen im Biotech-Sektor wider. Trotz deutlicher... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,770 | +5,18 % | Intellia Stock Declines Around 55% in 3 Months: Here's Why | ||
| TEMPUS AI | 60,50 | +0,83 % | TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company's Position to be a Leader | ||
| NUREXONE BIOLOGIC | 0,396 | -1,74 % | NurExone schafft Grundlage für First-in-Human-Perspektive mit ExoPTEN | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,836 | +2,93 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,850 | 0,00 % | Führungswechsel bei Ginkgo Bioworks: COO Reshma Shetty übergibt operative Verantwortung | ||
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| IOVANCE BIOTHERAPEUTICS | 2,317 | +6,41 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,672 | +4,02 % | Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) | ||
| SANA BIOTECHNOLOGY | 4,730 | +8,49 % | Sana Biotechnology Showcases Successful In Vivo Gene Editing of Stem Cells in Nature Publication | ||
| BIOMEA FUSION | 1,330 | +5,14 % | Biomea Fusion, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TERNS PHARMACEUTICALS | 34,400 | +4,88 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | ||
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,750 Euro und damit -1,69 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.